secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLAUKOS Corp (GKOS)
CIK:        0001192448
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001558370-23-012911
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glaukos Q2 net sales up 11% to $80.4M; raises FY2023 revenue guidance
---------------------------------------------------------------------

- Q2 net sales $80.4M, +11% YoY; glaucoma sales $61.9M (+10%), corneal health $18.5M (+11% YoY).
- GAAP net loss per diluted share ($0.68) vs ($0.96) in Q2 2022; non-GAAP loss per share ($0.55) vs ($0.83).
- Gross margin ~75%; non-GAAP gross margin ~82%; cash and investments $310M at quarter-end.
- 2023 net sales guidance raised to $304-308M from $295-300M previously.
- Operating loss narrowed to $29.1M from $36.8M; SG&A +6% to $53.1M, R&D +5% to $33.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1192448/000155837023012911/0001558370-23-012911-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1192448/000155837023012911/gkos-20230802x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-012911

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer